Key Points
- Paul Mahon sold 8,300 UTHR shares on Jan. 15 at an average price of $469.89 for about $3.90M, reducing his stake by 18.41% to 36,781 shares valued at roughly $17.28M.
- Quarterly results: United Therapeutics beat EPS expectations ($7.16 vs. $6.89), posted $799.5M in revenue (up 6.8% y/y), with an 18.83% ROE and a 40.65% net margin.
- Analyst view and valuation: the stock carries a "Moderate Buy" consensus with an average target of $509.50 (several firms have raised targets, UBS at $645), and the company trades around a $20.3B market cap with a P/E of ~17.9.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,283,024.09. This represents a 18.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
United Therapeutics Stock Down 0.8%
United Therapeutics stock opened at $471.99 on Friday. The firm has a fifty day simple moving average of $486.53 and a two-hundred day simple moving average of $406.79. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The company has a market capitalization of $20.32 billion, a PE ratio of 17.89, a P/E/G ratio of 2.47 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analysts' expectations of $812.87 million. During the same period last year, the firm earned $6.39 earnings per share. The company's revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on UTHR shares. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, UBS Group increased their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $509.50.
Get Our Latest Stock Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of UTHR. CWM LLC grew its stake in United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company's stock worth $1,492,000 after purchasing an additional 3,487 shares during the period. AXQ Capital LP lifted its position in United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company's stock valued at $1,117,000 after buying an additional 3,235 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company's stock valued at $14,027,000 after buying an additional 33,662 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in shares of United Therapeutics in the 3rd quarter worth about $8,351,000. Finally, Merit Financial Group LLC grew its position in shares of United Therapeutics by 56.3% in the 3rd quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company's stock worth $3,109,000 after buying an additional 2,672 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
